Insider transactions Bolt Biotherapeutics, Inc.

Stocks

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 17/07/2026 BST			5-day change	1st Jan Change
4.420 ^USD	+5.49%		+16.93%	-19.17%

05-12	Bolt Biotherapeutics reports first quarter 2026 financial results	RE
05-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Insider Transaction History

Latest insider transactions for Bolt Biotherapeutics, Inc.

Date	Insider	Type	Main position	Quantity	Price	Amount	% Market Cap.
10/06/26	Brian O'Callaghan	Free	Chairman	5,000	4.56	22.8K	0.2602%
10/06/26	Nicole Onetto	Free	Director	5,000	4.56	22.8K	0.2602%
10/06/26	Laura Berner	Free	Director	5,000	4.56	22.8K	0.2602%
10/06/26	Kathleen LaPorte	Free	Director	5,000	4.56	22.8K	0.2602%
10/06/26	Jakob Dupont	Free	Director	5,000	4.56	22.8K	0.2602%
28/01/26	Sarah Nemec	Buy	Controller/Auditor	8,125	4.61	576.25	0.4233%
28/01/26	Grant Yonehiro	Free	Chief Operating Officer	10,000	-	-	0.5210%
28/01/26	William Quinn	Buy	Chief Executive Officer	20,125	4.61	576.25	1.0485%
12/12/25	Nicole Onetto	Free	Director	15,622	-	-	0.8139%
12/12/25	Jakob Dupont	Free	Director	10,898	-	-	0.5678%
12/12/25	Grant Yonehiro	Free	Chief Operating Officer	152,054	-	-	7.9218%
12/12/25	Laura Berner	Free	Director	13,126	-	-	0.6838%
12/12/25	Sarah Nemec	Free	Controller/Auditor	61,990	-	-	3.2296%
12/12/25	William Quinn	Free	Chief Executive Officer	216,572	-	-	11.2831%
12/12/25	Brian O'Callaghan	Free	Chairman	15,806	-	-	0.8235%
12/12/25	Kathleen LaPorte	Free	Director	17,184	-	-	0.8953%
24/10/25	William Quinn	Buy	Chief Executive Officer	40,125	0.02	686.25	2.0905%
24/10/25	Sarah Nemec	Buy	Controller/Auditor	23,125	0.03	686.25	1.2048%
24/10/25	Grant Yonehiro	Free	Chief Operating Officer	30,000	-	-	1.5630%
27/05/25	Nicole Onetto	Free	Director	1,100	-	-	0.0029%
27/05/25	Jakob Dupont	Free	Director	1,100	-	-	0.0029%
27/05/25	Brian O'Callaghan	Free	Chairman	1,100	-	-	0.0029%
27/05/25	Laura Berner	Free	Director	1,100	-	-	0.0029%
27/05/25	Kathleen LaPorte	Free	Director	1,100	-	-	0.0029%
01/05/25	William Quinn	Buy	Chief Executive Officer	705,000	0.57	2.85K	1.8420%
01/05/25	Jakob Dupont	Free	Director	20,000	-	-	0.0523%
01/05/25	Grant Yonehiro	Free	Chief Operating Officer	350,000	-	-	0.9145%
01/05/25	Sarah Nemec	Buy	Controller/Auditor	231,000	0.57	2.85K	0.6036%
03/09/24	Jakob Dupont	Free	Director	66,984	-	-	0.1751%
23/07/24	William Quinn	Free	Chief Executive Officer	440,000	-	-	1.1540%
23/07/24	Grant Yonehiro	Free	Chief Operating Officer	155,000	-	-	0.4065%
23/07/24	Sarah Nemec	Free	Controller/Auditor	140,000	-	-	0.3672%
12/06/24	Brian O'Callaghan	Free	Chairman	22,000	-	-	0.0577%
12/06/24	Laura Berner	Free	Director	22,000	-	-	0.0577%
12/06/24	Mahendra Shah	Free	Director	22,000	-	-	0.0577%
12/06/24	James Healy	Free	Director	22,000	-	-	0.0577%
12/06/24	Nicole Onetto	Free	Director	22,000	-	-	0.0577%
12/06/24	Kathleen LaPorte	Free	Director	22,000	-	-	0.0577%
12/06/24	Frank Lee	Free	Director	22,000	-	-	0.0577%
15/05/24	Sarah Nemec	Other	Controller/Auditor	274,884	-	-	0.7210%
04/03/24	Grant Yonehiro	Free	Chief Operating Officer	235,000	-	-	0.6190%
04/03/24	Randall Schatzman	Free	Chief Executive Officer	654,000	-	-	1.7226%
04/03/24	Edith Perez	Free	Chief Technology Officer	235,000	-	-	0.6190%
04/03/24	William Quinn	Free	Chief Executive Officer	235,000	-	-	0.6190%
31/12/23	Grant Yonehiro	Buy	Chief Operating Officer	2,500	0.78	1.95K	0.0066%
31/12/23	Edith Perez	Buy	Chief Technology Officer	4,570	0.96	4.39K	0.0120%
31/12/23	Randall Schatzman	Buy	Chief Executive Officer	5,000	0.98	4.9K	0.0132%
12/12/23	William Quinn	Buy	Chief Executive Officer	11,829	0.95	11.23K	0.0312%
29/11/23	Vivo Capital LLC	Sell	Company	148,884	0.87	129K	0.3923%
21/11/23	Vivo Capital LLC	Sell	Company	3,400	0.90	3.06K	0.0090%